文献速递前列腺癌

≤60岁局限性前列腺癌患者低剂量率近距离放疗的长期肿瘤学结局与毒性

Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
PubMed 文献 · BJU Int · 2017-08-02

单中心回顾性分析597例治疗时≤60岁的局限性前列腺癌患者,接受低剂量率近距离放疗后中位随访8.9年。10年总生存率低危98%、中危99%、高危93%,前列腺癌特异生存率分别为99%、100%、95%,无复发生存率分别为95%、90%、87%。尿道狭窄是最常见的泌尿生殖不良事件(19例,3.2%),5年勃起功能保留率75%。

要点

  • 治疗时≤60岁局限性前列腺癌患者接受低剂量率近距离放疗后10年肿瘤控制良好。
  • 10年无复发生存率低危95%、中危90%、高危87%。
  • 尿道狭窄发生19例(3.2%),5年勃起功能保留率75%。

核心结论

  • 低剂量率近距离放疗是治疗时≤60岁男性前列腺癌的有效治疗方式,具有长期肿瘤控制效果。
  • 该治疗与低治疗相关毒性发生率相关,可考虑作为该患者群体前列腺癌的一线治疗。

研究设计与样本

  • 单中心回顾性研究,纳入截至2016年6月在该中心接受低剂量率近距离放疗的3262例患者中597例治疗时年龄≤60岁、植入后随访≥3年且至少有4次前列腺特异性抗原(PSA)测量(其中一次为基线)的患者。
  • 分析总生存期(OS)、前列腺癌特异生存期(PCSS)和无复发生存期(RFS),并前瞻性收集医生报告的不良事件和患者报告的症状评分。

主要发现

  • 中位年龄57岁(范围44-60岁),中位随访8.9年(范围1.5-17.2年),中位PSA随访5.9年(范围0.8-15年)。
  • 低危、中危和高危疾病分别占53%、37%和10%。
  • 植入后10年OS和PCSS:低危分别为98%和99%,中危分别为99%和100%,高危分别为93%和95%。
  • 植入后10年RFS(采用PSA最低值+2 ng/mL定义):低危95%、中危90%、高危87%。
  • 尿道狭窄是最常见的泌尿生殖不良事件,发生于19例患者(3.2%);植入后5年,治疗前勃起功能保留的患者中75%保持勃起功能。

关键数值与推荐

  • 低危组10年OS 98%、PCSS 99%、RFS 95%。
  • 中危组10年OS 99%、PCSS 100%、RFS 90%。
  • 高危组10年OS 93%、PCSS 95%、RFS 87%。
  • 尿道狭窄发生率3.2%(19例)。
  • 治疗前勃起功能保留的患者5年勃起功能保留率75%。

临床怎么用

  • 作者认为低剂量率近距离放疗可考虑作为治疗时≤60岁前列腺癌患者的一线治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report oncological and functional outcomes of men treated with low-dose-rate (LDR) prostate brachytherapy aged ≤60 years at time of treatment. PATIENTS AND METHODS: Of 3262 patients treated with LDR brachytherapy at our centre up to June 2016, we retrospectively identified 597 patients aged ≤60 years at treatment with ≥3-years post-implantation follow-up and four prostate-specific antigen (PSA) measurements, of which one was at baseline. Overall survival (OS), prostate cancer-specific survival (PCSS) and relapse free survival (RFS) were analysed together with prospectively collected physician-reported adverse events and patient-reported symptom scores. RESULTS: The median (range) age was 57 (44-60) years, follow-up was 8.9 (1.5-17.2) years, and PSA follow-up 5.9 (0.8-15) years. Low-, intermediate- and high-risk disease represented 53%, 37% and 10% of the patients, respectively. At 10 years after implantation OS and PCSS were 98% and 99% for low-risk, 99% and 100% for intermediate-risk, and 93% and 95% for high-risk disease, respectively. At 10 years after implantation RFS, using the PSA level nadir plus 2 ng/mL definition, was 95%, 90% and 87% for low-, intermediate-, and high-risk disease, respectively. Urinary stricture was the most common genitourinary adverse event occurring in 19 patients (3.2%). At 5 years after implantation erectile function was preserved in 75% of the patients who were potent before treatment. CONCLUSION: LDR brachytherapy is an effective treatment with long-term control of prostate cancer in men aged ≤60 years at time of treatment. It was associated with low rates of treatment-related toxicity and can be considered a first-line treatment for prostate cancer in this patient group.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Langley SEM, Soares R, Uribe J, et al. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU Int. 2017. PMID: 28670842. doi:10.1111/bju.13946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。